

Index

Note: Page references in *italics* refer to Figures; those in **bold** refer to Tables

- a**
- α2-macroglobulin 37
 - αIIbβ3 integrin receptor in platelet membrane 134
 - ε-aminocaproic acid 109
 - abnormal uterine bleeding (AUB) 30, 40
 - AUB-C 37
 - abscess, epidural 196
 - acquired von Willebrand syndrome (aVWS) 86
 - activated partial thromboplastin time (APTT) 5, 75, 103, 207
 - in FXI deficiency 122
 - in FVII deficiency 122
 - in VWD 88
 - acupuncture 192
 - ADAMTS13 83, 84
 - adenosine diphosphate (ADP) 142
 - adrenomedullin 39, 40
 - afibrinogenemia 9, 119, 121, 126, 127, 169, 217
 - alkaline hematin test 23, 120
 - alpha granule release assessment 142
 - amniocentesis 128, 144, 170, 172–4, 173, 209
 - third-trimester 173–4
 - in VWD 90
 - angiotensin II receptor type 2 (AGTR2) 40
 - ANKD26 mutations 144
 - antenatal diagnosis *see* prenatal diagnosis (PND)
 - anterior spinal artery syndrome 196
 - antiepileptics 216
 - antifibrinolytics 72, 77, 104
 - in factor XI deficiency 109
 - in heavy menstrual bleeding 55
 - in menorrhagia 127
 - in VWD 91
 - antithrombin 110
 - arachidonic acid 142
 - aromatase 33
 - aspirin 147
 - atherosclerosis 90
- b**
- Bernard–Soulier syndrome (BSS) 21, 50, 145, 147, 214, 215
 - bipolar radiofrequency ablation 57
 - Bleeders Not Yet Defined (NYD) 25
 - Bleeders of Unknown Cause (BUC) 25
 - bleeding assessment tools (BATs) 13–26, 48, 159
 - clinical utility of 25–6
 - condensed MCMDM-1VWD 20
 - evaluation of menstrual blood loss 23–4
 - International Society on Thrombosis and Haemostasis Bleeding Assessment Tool 21
 - molecular and clinical markers for diagnosis and management of Type 1 VWD (MCMDM-1VWD) 14–20
 - Pediatric Bleeding Questionnaire (PBQ) 20–1
 - Self-BAT 21–2
 - Self-PBQ 21–2
 - Vicenza Bleeding Questionnaire and Score 14
 - Vicenza-based, evolution of 13–14, 14, **15–19**
 - women’s studies using Vicenza-based bleeding tools 22–3
 - young women’s hematology and bleeding 25
 - breastfeeding 90
 - broad ligament hematoma 59
 - butorphanol 193

Inherited Bleeding Disorders in Women, Second Edition.

Edited by Rezan A. Kadir, Paula D. James, and Christine A. Lee.

© 2019 John Wiley & Sons, Ltd. Published 2019 by John Wiley & Sons, Ltd.

C

carbonic anhydrase 9 36
 Cardiff Penthrane
 inhaler 192
 cascade model 4
 cell-based model of
 hemostasis 4–5, 4
 cell-free fetal DNA (cffDNA)
 in maternal
 circulation 177
 central nervous system (CNS)
 bleeding 136
 cephalohematoma 209, 211
 cephalosporins 216
 cervical cerclage 128
 cervical lesions 123
 cervicitis 123
 cesarean section in factor XI
 deficiency 108
 CHAMP FVIII database 153
 CHBMP database 153
 chemokines 35
 C 35
 CC 35
 CCL11 35
 CCL2 35
 CX3C 35
 CXC 35
 CXCL10 35
 CXCL8 35, 36
 chorionic villus sampling
 (CVS) 74, 128, 144,
 170, 171–2, 209
 in VWD 90
 circumcision
 factor VI deficiency 111
 in newborn 213
 Clauss fibrinogen 9
 clotting factors
 in heavy menstrual
 bleeding 56
 in menorrhagia 127
 coagulation disorders 215–18
 coagulation factors,
 rare 216–18, 217
 coagulation pathways 3, 37
 collagen 3, 142
 collagens I, III, IV and
 VI 35

combined hormonal
 contraceptives (COCs)
 factor XI deficiency and 104
 in heavy menstrual
 bleeding 53, 58
 in menorrhagia 127
 combined oral contraceptive
 pill (COCP) 9, 53, 147
 in VWD menorrhagia 92
 combined spinal-epidural
 (CSE) 192, 195
 Condensed MCMDM-1VWD
 Bleeding
 Questionnaire 22, 26
 congenital amegakaryocytic
 thrombocytopenia
 (CAMT) 145, 214
 congenital bleeding disorders
 detection 209–13
 newborns presenting
 with bleeding
 symptoms 211–13
 newborns with positive
 family history of
 bleeding
 disorder 209–11
 optimal mode of
 delivery 210–11
 prenatal
 diagnosis 209–10
 developmental
 hemostasis 205–6
 diagnostic algorithm 206
 laboratory hemostatic
 evaluation 208–9
 management
 congenital bleeding
 disorders 218–21, 220
 when newborn is
 bleeding 219–21
 presentation 213–18
 primary hemostasis 206–7
 secondary
 hemostasis 207–8
 connective tissue growth
 factor (CTGF) 40
 consanguineous
 marriage 231
 cordocentesis 170, 174–6, 175

corpus luteum, bleeding
 from 6
 cryoablation 57
 cryoprecipitate 124
 cumulus oophorus 32

d
 Danazol 54
 DDAVP 70, 76, 109, 146
 in heavy menstrual
 bleeding 55–6, 58
 in inherited platelet
 defects 144
 nasal spray 58
 in VWD type 2 and
 type 3 53
 deamino-8-arginine
 vasopressin *see* DDAVP
 decidualization 34, 35
 dense granule release
 assessment 142
 dental surgery 146–7
 depot medroxyprogesterone
 acetate (DMPA) 54
 desmopressin 55–6, 75, 93,
 104, 109, 221
 in factor XI deficiency 110
 in heavy menstrual
 bleeding 55–6
 in hemophilia A 110
 in menorrhagia 127
 for menorrhagia in women
 with VWD 92
 in VWD 90, 110
 see also DDAVP
 desogestrel (Cerazette®) 54
 digital PCR (dPCR) 179
 disseminated intravascular
 coagulation
 (DIC) 109, 214
 double uterotonics 77
 droplet digital PCR
 (ddPCR) 179
 Duchenne muscular
 dystrophy 181
 dural puncture 195
 dyschezia 59
 dysfibrinogenemia 9, 121,
 122, 127

- dysmenorrhea 59
dyspareunia, deep 59
- e**
Ehlers--Danlos syndrome 7
Eltrombopag 147
embryo culture 181
endometrial ablation
 in heavy menstrual
 bleeding 56–7
 in menorrhagia 127
endometrial hyperplasia 60
endometrial polyps 123
endometriosis 6, 59–60, 121
 link between IBM and 60
endothelin-1 (ET-1) 37
enflurane 193
Entonox 192
enzyme-linked
 immunosorbent assay
 (ELISA) 9, 142
epidural 192
epidural abscess 196
epidural hematoma 196, 199
epinephrine 142
episiotomy 107
estradiol 30, 1, 33
estrogen receptor (ER) 33
 ER α 33, 34
 ER β 33
ethinyl estradiol, low-dose 53
European Association for
 Haemophilia and
 Allied Disorders
 (EAHAD) international
 database 66, 153
European Molecular and
 Clinical Markers for
 the Diagnosis and
 Management of Type 1
 von Willebrand Disease
 (MCMDM-1VWD)
 study 20
European Network of the Rare
 Bleeding Disorders
 (EN-RBD) 117
extracranial hemorrhage (ECH)
 in newborn 209,
 211–12
- f**
factor II *see* prothrombin
factor V 3
factor V deficiency 5, 10, 50,
 117, 122, 126, 169
 in newborn 217–18
 postpartum hemorrhage
 in 121
 prevalence 117
factor V + factor VIII deficiency,
 combined 10, 66, 117,
 122, 124, 169
 prevalence 117
factor Va 5
factor VII 3, 9, 37, 101
 postpartum hemorrhage
 in 122
factor VII deficiency 5, 10,
 50, 117, 169
 in newborn 218
 prenatal diagnosis 180
 prevalence 117
 severe 126, 128
factor VIIa 101
factor VIII (FVIII:C) 3, 9, 84
 in hemophilia, neonate
 76
 in pregnancy 192
factor VIII deficiency 153
 in newborn 219
factor VIIIa 5
factor IX 192
 in hemophilia, neonate
 76
 in pregnancy 192
factor IX deficiency 5, 153,
 169, 219
 see also hemophilia B
factor IXa 4
factor X 9, 101
factor X deficiency 10, 50,
 122, 124, 169
 in newborn 218
 prenatal diagnosis 180
 prevalence 117
 severe 126, 128
factor XI 104, 106–7
 concentrates 109
 in pregnancy 192
factor XI deficiency (FXI) 1,
 10, 45, 59, 101–11, 124,
 127, 128
 in Ashkenazi Jews 211
 bleeding manifestations and
 diagnosis 103–4
 coagulation cascade 102
 gynecological
 surgery 104–5
 heavy menstrual
 bleeding 103–4
 hysterectomy 104
 incidence and
 inheritance 101–3
 inheritance 169
 neonatal bleeding 111–12
 in newborn 218
 neuroaxial analgesia and
 anesthesia 108
 postpartum hemorrhage
 and 122
 postpartum period,
 management of 108–9
 pregnancy and 105–8,
 106, 192
 antenatal
 management 105
 bleeding tests 105–7
 bleeding
 phenotype 105–6
 blood group 106
 factor XI level 106–7
 fibrin density
 network 107
 global testof
 hemostasis 107
 labor delivery 107–8
 in mild/moderate FXI
 deficiency 108
 requiring cesarean
 section 108
 in severe FXI
 deficiency 107–8
 peripartum
 management 105–7
 prevalence 117, 118
 structure and function in
 coagulation 101, 102
 treatment 109–11

- factor XI replacement therapy 109–10
- factor XIa 3, 5
- factor XIII 4, 5, 37
- factor XIII deficiency 5, 10, 50, 59, 117, 124, 127, 128, 169
- miscarriage in 121
- in newborn 218, 219
- PPH in 121
- phenotype 122
- prenatal diagnosis 180
- prevalence 117
- severe 126
- fantanyl 193
- fibrin 4
- fibrinogen 4, 9
- in pregnancy 127
- fibrinogen deficiency 10, 50, 124, 128
- miscarriage in 121
- in newborn 217
- phenotype 122
- prevalence 117
- thrombin time (TT) in 122
- fibrinolysis 4, 36–7
- fibroids 6, 54, 121
- factor XI deficiency 104
- submucosal 123
- uterine 50, 60
- fibronectin 3
- flow cytometry 142, 143
- fluorescent *in situ* hybridization (FISH) 172, 181
- follicle aromatase 30
- free fetal DNA (ffDNA) 170
- free fluid ablation 57
- fresh frozen plasma (FFP) 104, 109, 110, 124
- FSH 30
- g**
- gene therapy in Wiskott–Aldrich syndrome 147
- genetic counselling 167–70
- clinical phenotype 169
- confirmation of diagnosis 168
- inheritance 168
- reproductive options 169, 70
- genome editing 147
- Glanzmann thrombasthenia 21, 50, 137, 144–5, 146, 147, 214, 215
- in French gypsies 211
- glycoprotein Ib 3
- glycoprotein Ib-IX-V complex 134
- glycoprotein IIb/IIIa platelet receptor 3
- glycoprotein VI 3, 134
- gonadotrophin-releasing hormone 30
- agonist in heavy menstrual bleeding 54
- pulse generator 31
- gonadotrophins 30
- gray platelet syndrome 214
- growth factor binding protein-1 35
- gynecology 45–61
- h**
- heat shock proteins 1A and 1B 40
- heavy menstrual bleeding (HMB) 1, 37, 40, 45, 47, 47, 48–9, 119–21, **20**
- algorithm of management 51
- diagnosis 45–6
- endometriosis 59–60
- IBD and **49–50**
- management 51–2
- incidence 29
- investigations 50–1
- management of acute episodes 58
- COCs 58
- LNG-IUS 58
- nasal DDAVP spray 58
- medical treatment 51–8
- hormonal treatments 51–5
- non-hormonal treatments 55–6
- surgical interventions 56–8
- ovulation bleeding 59
- as predictor for bleeding disorders 46–7
- screening for bleeding disorders in 47–8
- hemarthroses 136, 213
- hematoma
- broad ligament 59
- epidural 196, 199
- muscle 136
- in newborn 213
- retroperitoneal 59
- spinal 196, 199
- subgaleal 209, 211
- hematopoietic stem cell transplantation in inherited platelet defects 145
- hemoperitoneum 59
- hemophilia 5
- prenatal diagnosis of 177–80, 178
- hemophilia A (HA) 5, 22, 57, 117, 192, 215
- desmopressin in 110
- FVIII:C levels 154, 155
- genetic analysis 160–2
- guidelines 164
- inheritance 168
- phenotypic analysis 154–6
- prevalence 153, **154**
- severity 154
- variant types **160**
- variants 153
- hemophilia A, carriers of 65–79, 192
- bleeding disorders in 68–73
- FVIII or FIX deficiency 68–9
- FVIII:C/FIX:C levels and bleeding scores in 71
- imprecise designation with low factor level 70

- low FVIII or FIX
 - levels 69
 - menorrhagia 72
 - prevalence 70
 - protection from thrombosis 73
 - terminology 69–70
 - treatment of bleeding episodes 70–1
 - type of bleeding episodes 72
- care of carriers 77–9
- delayed genetic diagnosis/ carriership 68
- F8 or F9 gene mutation 66
- genetic vs coagulation testing 66–7
- inheritance 65, 66
- pregnancy in 73–7
- preimplantation genetic diagnosis (PGD) 67
- prenatal diagnosis (PND) 67
- quality of life 73
- screening of 65–6
- timing of genetic testing 67–8
- vignettes 78–9
- hemophilia B 5, 117, 215, 222
 - in Amish communities 211
 - FIX:C levels 156
 - genetic analysis 162–3
 - guidelines 164
 - inheritance 65, 66, 168
 - phenotypic analysis 156–7
 - in pregnancy 192
 - prevalence 153, **154**
 - severity 154
 - variant types **160**
 - variants 153
- hemophilia B, carriers
 - of 65–79
 - bleeding disorders
 - in 68–73
 - FVIII or FIX deficiency 68–9
 - FVIII:C/FIX:C levels and bleeding scores in 71
 - imprecise designation
 - with low factor level 70
 - low FVIII or FIX levels 69
 - menorrhagia 72
 - prevalence 70
 - protection from thrombosis 73
 - terminology 69–70
 - treatment of bleeding episodes 70–1
 - type of bleeding episodes 72
- care of carriers 77–9
- delayed genetic diagnosis/ carriership 68
- F8 or F9 gene mutation 66
- genetic vs coagulation testing 66–7
- inheritance 65, 66, 168
- pregnancy in 73–7
- preimplantation genetic diagnosis (PGD) 67
- prenatal diagnosis (PND) 67
- quality of life of carriers 73
- screening of 65–6
- timing of genetic testing 67–8
- vignettes 78–9
- hemorrhage
 - extracranial (ECH) 209
 - intracranial (ICH) 68, 76–7, 209, 212, 212
 - see also* postpartum hemorrhage
- hemostasis
 - cell-based model of 4–5, 4
 - defects of 5
 - fibrinolysis 4
 - normal 1–3, 2
 - primary 3
 - secondary 3–4
- hemostatic function platelet function analyzer (PFA-200) 89
- hemostatic risk 191–2
- heparin 109
- hepatitis A and B viruses 91
- Hermansky–Pudlak syndrome 145
- high forceps 210
- hormone replacement therapy (HRT) 9, 60
- hyperplasia 6, 121
- hypofibrinogenemia 9, 121, 127, 217
 - PPH in 122
- hyponatremia 90
- hypoprothrombinemia 169
- hypothalamic-pituitaryovarian axis 31, 32
- hypoxia inducible factor 1 α (HIF-1 α) 36, 39
- hysterectomy
 - in heavy menstrual bleeding 57–8
 - in menorrhagia 127
- hysteroscopy 50, 57
- i**
- immune thrombocytopenias (ITPs) 214
- immunoglobulin 109
- in vitro* fertilization (IVF) 181, 210
- inherited bleeding disorder (IBDs) 1–10, 45, 48
 - bleeding, clinical presentation of 5–6
 - diagnosis 6
 - heavy menstrual bleeding and **49–50, 61**
 - history 6–7, 7
 - medication history 6
 - pastmedical history and family history 6
- investigations 7–10
 - hemostatic assays
 - laboratory assessment of hematological and coagulation system 7, **8–9**
 - preanalytical factors in coagulation testing 9–10

- investigations (*Contd.*)
 specialized tests of
 coagulation 10
 physical assessment 6–7
 prevalence 13
 phenotypic analysis
 of 157–60
 inherited platelet defects
 (IPDs) 10, 133–48,
 213–15
 case histories 147–8
 causative gene **138–41**, 143
 future directions 147
 investigation 137–43
 management 144–7
 dental surgery 146–7
 menorrhagia 147
 pregnancy and
 delivery 145–6
 supportive
 management 147
 surgery 146–7
 treatment options 144–5
 normal platelet
 function 133–4
 prenatal diagnosis 143–4
 presentation 136–7
 inherited thrombocytopenias
 134, 136
 related to GATA-1
 mutations 314
 integrin receptor $\alpha 2\beta 1$ 134
 interleukin (IL)
 IL-6 35
 IL-15 35
 intermenstrual bleeding,
 irregular 60
 International Society on
 Thrombosis and
 Haemostasis (ISTH)
 Scientific and Standardization
 Committee
 (SSC) 13–14
 International Society on
 Thrombosis and
 Haemostasis Bleeding
 Assessment Tool
 (ISTH-BAT) 6, 21,
 22, 25, 137
 international normalized ratio
 (INR) 207
 intracranial hemorrhage (ICH)
 68, 76–7
 in newborn 209, 211–12,
 212
 intracytoplasmic sperm
 injection (ICSI) 181
 intramuscular analgesia
 193
 intravenous opioid
 administration 193
 iron deficiency 48
 iron deficiency anemia 50
 isoflurane 193
 isoniazid 216
- k**
 kisspeptin 31
- l**
 labor pain 191
 non-pharmacological
 management 192
 pharmacological
 management 192–
 201
 general anesthesia 201
 inhalation
 analgesia 192–3
 opioid analgesia 193–4
 postoperative pain 201
 regional (neuraxial)
 analgesia and
 anesthesia 194–9
 coagulopathy and risk of
 neurological
 complications 195–6
 guidance for use in
 IBDs 198–9, **198**, **200**
 regional blockade in
 IBD 197–8
 risks and complications 195
 techniques of blockade
 194–5
 regional block techniques,
 other 199–201
 paracervical block 199–200
 pudendal block 200–1
 laminin 3
 Lebanon
 inherited bleeding disorders
 in 225
 inherited factor VII
 deficiency 230–1, 232
 type 3 VWD 229–30, 231
 leptin 31
 levonorgestrel 53
 levonorgestrel intrauterine
 device (IUD) 159
 in menorrhagia 127
 levonorgestrel intrauterine
 system (IUS)
 factor XI deficiency
 and 104
 in menorrhagia 147
 levonorgestrel-releasing
 intrauterine device 92
 levonorgestrel-releasing
 intrauterine system
 (LNG-IUS) in heavy
 menstrual
 bleeding 51–2, 52, 58
 light transmission aggregometry
 (LTA) 142, 143
 loss of resistance
 technique 194
 low molecular weight heparin
 in VWD 94
 lumiaggregometry 21, 142
 luminometry 142
 lupus anticoagulant 9
 lyonization 68
- m**
 macrophages 36
 macrothrombo
 cytopenias 214
 Malaysia 232
 inherited bleeding disorders
 in 225–9
 Glanzmann
 thrombasthenia 228,
 231
 VWD type 2 227–8,
 231, 232
 massively parallel sequencing
 (MPS) 179

- matrix metalloproteinases (MMPs) 36, 37
- MCMDM-1VWD Bleeding Questionnaire 20, 26
- mean platelet volume (MPV) 134
- Mediterranean microthrombotic cytopenia 214
- medroxyprogesterone acetate 58
- megakaryocytes 133
- menarche 31
- menorrhagia 5–6, 26, 70, 119–21, **120**
 differential diagnosis 123–4
 IPDs presenting with 136
 management 147
 vWD and 87–8, 91, 92
- menstrual blood loss (MBL) 45–6
- menstrual cup (Mooncup®) 46
- menstruation 29–40
 control of bleeding 37–8
 endometrial regeneration 40
 endometrial repair 38–9
 endometrium 33–4
 neuroendocrine hormones 30–1
 normal menstruation 29–30
 duration 30
 volume of blood loss 30
 ovarian follicle development and endocrine function 31–3
 physiology of 29–31
 proliferative phase 40
 secretory phase 34–5
- meperidine 193, 194
- meptazinol 193
- mesenchymal-to-epithelial transition (MET) 39
- methoxyflurane 192
- miscarriages 121
- Mittelschmerz (midcycle pain) 59
- molecular and clinical markers for the diagnosis and management of Type 1 VWD (MCMDM-1VWD) 14–20
 condensed 20
- monogenic diseases (MGD) 181
- morphine 193
- mucocutaneous type bleeding 209
- muscle hematomas 136
- musculoskeletal bleeding 209
- MYH9-related disorder 137, 142, 214
- MYH9-related thrombocytopenia 147
- n**
- naloxone 193
- natural killer (NK) cells 34
- neonatal alloimmune thrombocytopenia 137, 146
- next-generation sequencing (NGS) 10, 143
- NF-κB 36
- nitrous oxide 193
- non-invasive prenatal diagnosis (NIPD) 176–7
- non-resectoscopic endometrial ablation (NREA) 56
- non-steroidal anti-inflammatory drugs (NSAIDs) 55, 72, 93, 147
- norethisterone 58
- NovoSeven® in inherited platelet defects 144–5
- o**
- obstetric cholestasis 196
- ocular albinism 7
- oral progesterone tablets 147
- ovarian cyst hemorrhagic 6, 59, 61, 121
 ruptured 61, 137
- ovulation bleeding 59
- oxytocin 195
- p**
- pain, definition 191
- Pakistan, inherited bleeding disorders in, type 3 VWD 225–7, 231, 232
- PALMCOEIN acronym 30
- patient-controlled analgesia (PCA) 193
- patient-controlled epidural analgesia (PCEA) 194
- Pediatric Bleeding Questionnaire (PBQ) 20–1, 25, 26
 Self 21–2
- pelvic pain, chronic 59
- petechiae 209
- pethidine 193
- PGE2 37
- PGF2α 36, 37
- Phillipp screening tool 24, 25
- Pictorial Blood Assessment Chart (PBAC) 23–5, 23–4, 46, 104, 120, 136, 159, 232
- plasmin 4, 37
- plasminogen 37, 207
- plasminogen activator inhibitor (PAI) 37
- platelet activation 3
- platelet activation status 134
- platelet adhesion 3
- platelet aggregation 3, 134
- platelet beta 1 integrin 3
- platelet count 134
- platelet formation 134, 135
- platelet function analyzer (PFA)-100
- platelet function disorders 5, 45, 103, 214–15
- platelet granules 134
 alpha 134
 dense 134
- platelet plug formation 3

- platelet transfusion in inherited
 - platelet defects 145
 - Poiseuille's equation 37, 38
 - polyps 6, 121
 - endometrial 123
 - factor XI deficiency 104
 - uterine 50, 60
 - postcircumcision
 - bleeding 209
 - postmenopausal bleeding
 - (PMB) 60
 - postpartum hemorrhage
 - (PPH) 6, 70, 77, 87–8, 103, **120**, 121–2
 - in factor XI deficiency 105
 - pre-eclampsia 90, 196
 - pregnancy in hemophilia
 - carriers 73–7
 - antenatal management 73–5
 - changes of factor levels 74–5
 - preimplantation genetic diagnosis (PGD) 74
 - prenatal diagnosis 73–4
 - perinatal management 75–7
 - cranial imaging 76
 - intracranial hemorrhage and relation to mode of delivery 76–7
 - mother - regional block 75
 - neonate 75–6
 - postpartum hemorrhage 77
 - preimplantation embryo selection (PIES) 210
 - preimplantation genetic diagnosis 181–3
 - carrier attitudes 183–4
 - experiences and psychological effects 184–5
 - towards prenatal diagnosis 183–4
 - termination of pregnancy 184, 185
 - Premarin 58
 - prenatal diagnosis
 - (PND) 167–85
 - carrier attitudes
 - towards 183–4
 - of factor VII, factor X and factor XIII deficiencies 180
 - of hemophilia 177–80, 178
 - invasive 170–6
 - non-invasive (NIPD) 176–7
 - of rare bleeding disorders 180–1
 - of VWD 180
 - primary hemostasis 83
 - prion diseases 91
 - progesterone 30, 34, 35–6
 - progesterone receptor (PR) 33
 - PRA 34
 - PRB 34
 - progestin-only “mini-pill” 54
 - progestogens in heavy menstrual bleeding 53–4, 58
 - prostaglandin E2 35
 - prostaglandin F2 α 35
 - protease tissue plasminogen activator (tPA) 4
 - prothrombin 5, 9, 37
 - prothrombin complex concentrates (PCCs), 124, 126
 - prothrombin deficiency 10, 50, 126
 - in newborn 217
 - PPH in 122
 - prevalence 117
 - prothrombin time (PT) 5, 207
 - puberty *see* menarche
 - purpura 209
- r**
- rare bleeding disorders (RBDs) 117–28
 - classification **126**
 - clinical symptoms 118–19
 - differential diagnosis in menorrhagia 123–4
 - gender 118
 - global distribution 118
 - gynecological and obstetrical manifestations 119–22
 - laboratory diagnosis 122–3
 - phenotype 122
 - molecular diagnosis 122–3
 - prenatal diagnosis of 180–1
 - treatment 124–8, **125**
 - clotting factor replacement 124–7
 - management of pregnancy and childbirth 127–8
 - treatment of menorrhagia 127
 - receiver operator curve (ROC) 20–1
 - recombinant factor VIIa (rFVIIa) 109, 110–11, 126
 - in inherited platelet defects 144–5
 - recombinant factor XIIIa 104, 126
 - recombinant VWF concentrate 91
 - relative haplotype dosage (RHDO) 179–80
 - relative mutation dosage (RMD) 179
 - remifentanyl 193, 194, 202
 - resectoscope 56
 - resectoscopic endometrial ablation (REA) 56–7
 - restriction fragment length polymorphisms (RFLPs) 177
 - retrograde menstruation theory 59
 - retroperitoneal hematoma 59
 - rifampin 216
 - ristocetin 142, 215
 - ristocetin co-factor assay, VWF:RCo 89
 - rotational thromboelastometry (ROTEM) 10
 - RUNX1 mutation 144

s

Self-BAT 21–2
 Self-PBQ 21–2
 sevoflurane 193
 solvent detergent (SD) FFP 110
 spinal hematoma 196, 199
 subgaleal hematoma 209, 211
 submucosal fibroids 123
 Swyer syndrome 68

t

termination of
 pregnancy 184, 185
 hemophilia A and B
 and 73–4
 thermal balloon ablation 57
 thrombin 3, 4, 5, 37
 thrombin activatable
 fibrinolysis inhibitor
 (TAFI) 5, 101
 thrombin generation test
 (TGT) 107
 thrombocytopenia 37, 146,
 213–14
 inheriteds 134, 136, 314
 thrombocytopenia with absent
 radii (TAR) 214
 thromboelastography
 (TEG) 10, 107
 thromboelastometry
 (ROTEM) 107
 tissue factor (TF) 3, 37, 101
 tissue factor pathway inhibitor
 (TFPI) 101
 tissue inhibitors of
 metalloproteinases
 (TIMPSs) 38
 tissue plasminogen activator
 (u-PA) 37
 tramadol 193
 tranexamic acid 6, 93, 94,
 108, 109, 127, 147, 197
 factor XI deficiency 104
 in heavy menstrual
 bleeding 55
 in inherited platelet
 defects 144
 for menorrhagia in
 VWD 92

 in VWD 91
 transcervical endometrial
 resection 57
 transdermal contraceptive
 patches 53
 transforming growth factor β 2
 (TGF β 2) 40
 Tuohy's curved bevel
 needle 194, 195, 196
 Turner syndrome 68, 156

u

Ulipristal acetate (UPA)
 (Esmya[®]) in heavy
 menstrual
 bleeding 54–5
 ultra-large (ULVWF) VWF
 multimers 207
 ultrasound examination,
 fetal 170
 umbilical stump
 bleeding 212
 ureteric silk catheters 194
 urokinase-like plasminogen
 activator (uPA) 4
 uterine fibroid 50, 60
 uterine natural killer (uNK)
 cells 34–5
 uterine polyps 50, 60
 uterine tony 121

v

vaccines 212–13
 vacuum extraction 210
 vaginal rings 53
 vaginal tears 107, 123
 valerate and dienogest (E2V/
 DNG) contraceptive
 pill 53
 variant Creutz-Jakob
 disease 91
 vascular endothelial growth
 factor (VEGF) 36
 VEGFR-1 (flt-1) 39
 VEGFR-2 (KDR) 39
 VEGR 39, 40
 venepuncture 212–13
 vessel radius, effect on on
 blood flow 37, 38

Vicenza Bleeding

 Questionnaire and
 Score 14
 vitamin K 76, 146
 at birth 211, 212–13
 metabolism 122
 vitamin K deficiency bleeding
 (VKDB) in
 infancy 216
 vitamin K-dependent
 coagulation factor
 deficiency (VKCFD)
 117, 122
 von Willebrand disease
 (VWD) 1, 5, 6, 9, 37,
 45, 47, 57, 83–96, 103,
 117, 142, 215–16
 cases 94–6
 classification and
 inheritance 85, **86**
 clinical presentation 87
 diagnosis 10, 13, 14, 88–9
 inheritance 168–9
 VWF:Ag levels 154
 family testing 89–90
 genetic analysis 163–4
 genetic analysis 89–90
 guidelines 164
 gynecological bleeding,
 management of 91
 history 83
 inheritance 168–9
 laboratory testing 88–9
 management 90–1
 menorrhagia and 87–8,
 91, 92
 neonatal management 94
 obstetric
 management 92–4
 antenatal
 management 92–3
 intrapartum
 management 93
 postpartum
 management 93–4
 pre-pregnancy
 management 92
 phenotypic analysis 157,
158

- von Willebrand disease (VWD) (*Contd.*)
 - postpartum hemorrhage and 87–8
 - prenatal diagnosis 89–90, 180
 - platelet-type VWD 214
 - type 1 85, 87–8, 89, 90, 92, 93, 153
 - normal clotting factor levels 192
 - type 2 48, 53, 85, 89, 90, 92, 93, 153
 - type 2A 169
 - type 2B 169, 214
 - type 2M 154, 169
 - type 2N 154, 169
 - type 3 48, 53, 85–7, 89–90, 92, 93–4, 153, 219
 - inheritance 169
 - in pregnancy 192
 - variance 153
 - von Willebrand factor (VWF)
 - 3, 5, 9, 37, 47, 103
 - deficiency 153
 - levels and prevalence of VWD 84
 - menorrhagia and 87–8
 - menstrual cycle, pregnancy and 84–5
 - postpartum hemorrhage and 87–8
 - structure and function 83–4
 - von Willebrand factor antigen (VWF:Ag. VWF:Ac) 192
 - von Willebrand syndrome, acquired (aVWS) 86
 - von Willebrand factor
 - pseudogene (VWFp1) 153
 - VWF *see* von Willebrand factor (VWF)
- W**
- warfarin 216
 - Willebrand disease (VWD) 66
 - Wiskott–Aldrich syndrome (WAS) 145, 147, 214
 - World Federation of Hemophilia (WFH) 117
- X**
- X-linked thrombocytopenia 147